Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Finch Therapeutics Group Inc (NQ: FNCH )

2.063 -0.057 (-2.67%)
Streaming Delayed Price Updated: 2:33 PM EDT, May 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Finch Therapeutics Group Inc

Acurx Pharmaceuticals Share Price And Volume Are Surging Ahead Of Phase 2b Trial Data Release ($ACXP)
Via AB Newswire
Topics Death
Exposures Death
Finch Announces Reverse Stock Split of Common Stock
From Finch Therapeutics Group, Inc.
Via GlobeNewswire
Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
From Finch Therapeutics Group, Inc.
Via GlobeNewswire
Finch Therapeutics Announces Executive Leadership Transitions
From Finch Therapeutics Group, Inc.
Via GlobeNewswire
Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women’s Hospital and Updates to University of Minnesota License Agreement
From Finch Therapeutics Group, Inc.
Via GlobeNewswire
Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
From Finch Therapeutics Group, Inc.
Via GlobeNewswire
Acurx Pharmaceuticals CEO Is Confident His Ibezapolstat Can Earn Front-Line Designation To Treat C. difficile…Here’s Why ($ACXP)
Via AB Newswire
Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets
From Finch Therapeutics Group, Inc.
Via GlobeNewswire
Finch Therapeutics Provides Corporate Updates and Reports Third Quarter 2022 Financial Results
From Finch Therapeutics Group, Inc.
Via GlobeNewswire
Finch Therapeutics to Present at the Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference
From Finch Therapeutics Group, Inc.
Via GlobeNewswire
Finch Therapeutics Presents PRISM-EXT Biomarker Data at ACG 2022 and Proceeds with Patient Dosing in Phase 3 Trial of CP101 in Recurrent C. Difficile Infection
From Finch Therapeutics Group, Inc.
Via GlobeNewswire
Acurx Pharmaceuticals Is Under The Radar, That’s Excellent News For Investors Wanting Exposure To Billion Dollar CDI Treatment Market ($ACXP)
Via AB Newswire
Exposures Product Safety
Acurx Pharmaceuticals Stands As Front-Line CDI Treatment Contender After Pfizer Misses Primary Endpoint In CDI Drug Trial (NASDAQ: ACXP)
Via AB Newswire
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.